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following either intravenous (n¼2) or subcutaneous (n¼2)
injection of cells as well as following skin graft rejection.
These results suggest that exposure to donor cells
following reduced intensity conditioning can result in
robust immune modulation of antibody responses to
allogeneic cells. B cell unresponsiveness is stable and does
not depend on persistence of unresponsiveness at the T
cell level or the persistence of donor cells. We speculate
that this mechanism of immune modulation of B cell
responses by allogeneic cells may play an important role
in facilitating induction of transplantation tolerance
through HCT.355
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Graft-versus-host disease (GVHD) remains a frequent
complication of hematopoietic cell transplantation (HCT)
with skin being a principal target organ. Murine models
have provided some insight into the mechanisms of this
complex disease process. However, mouse skin differs
from human skin, and results of studies in rodents may
not translate well to the clinic. The pig is a well-
recognized animal model for preclinical studies of skin
including dermal toxicology, transdermal drug delivery
and wound healing. Unlike skin of rodents, dogs or non-
human primates, porcine skin is similar to human skin
in terms of structure of epidermal rete ridges, hair
follicle structure and density, and presence of sweat
glands and subcutaneous fat. Because of the similarities
of pig skin to human skin and availability of swine with
deﬁned MHC genes, MGH miniature swine provide
a valuable pre-clinical model of HCT for studies of graft-
versus-host disease. HCT between MHC matched or
mismatched animals can be performed to mimic clinical
HCT scenarios with outcomes that closely resemble
those observed in human HCT recipients. With myeloa-
blative conditioning, HCT across MHC barriers is most
often fatal, with animals developing severe grade III-IV
GVHD involving the gastrointestinal tract (GI), liver and
skin. We have developed a comprehensive GVHD scoring
system for pigs which parallels that used clinically (see
chart). Unlike rodent models, miniature swine provide
an opportunity to perform extended longitudinal
studies, since multiple tissue biopsies can be taken
without the need to sacriﬁce the animal. Given the
similarities of GVHD in pigs and humans, we hope that
the utilization of the pig and scoring system facilitates
scientiﬁc discourse between the laboratory and the
clinic. We anticipate that results of swine studies will be
applicable to the development of new strategies to
improve GVHD identiﬁcation and treatment in clinical
HCT scenarios.356
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Background: Allogeneic HSCT from an HLA-matched sibling
donor is the recommended treatment approach in patients
with SAA, at least up to the age of 40 years. Cyclophospha-
mide (Cy)-ATG is the standard, non-myeloablative condi-
tioning regimen, while BM stem cells are the preferred
source of engraftment.
Aims:We have already published our data regarding the use
of PBSCs in patients with SAA conditioned with the Fludar-
abine (Flu)-Cy regimen (EBMT, Czech Republic 2005, Poster
Abst # 782 / CBMTG, Montreal 2008, oral Abst # 02). In this
single arm prospective study, we investigated the use of
FlueCy to allograft SAA patients >20 years old, using PBSCs.
Patients & methods: In the time period between May 2003
and December 2009, 53 heavily pre-transfused SAA patients
received allogeneic HLA- identical sibling PBSCs at the BMT
unit of Nasser institute, Cairo, Egypt. All patients were above
the age of 20 years (range 21- 41 years, mean 27 years). The
regimen consisted of Flu at a total dose ranging from 75mg-
120mg/ m2, and a total Cy dose of 200mg/kg. Our primary
endpoints were incidence and severity of chronic GVHD, as
well as DFS & OS. Cyclosporine & Methotrexate were used for
GVHD prophylaxis.
